Activity Director: James Tsai, MD, MBA

CME Reviewer: Matthew J. Gray, MD

Video 1 — Basic Science and Clinical Introduction

Joseph Caprioli, MD — Paul L. Kaufman, MD

Video 2 — New Drug Classes

Eydie Miller-Ellis, MD — Robert Noecker, MD, MBA

Video 3 — Improved Drug Use and Delivery

Angelo Tanna, MD — Rohit Varma, MD, MPH

Learning Objectives

  • Treat glaucoma patients so as to most effectively reduce their risk of glaucomatous progression and visual loss

  • Explain the basic pathophysiology of glaucoma, from IOP to newer mechanisms such as the role of ocular perfusion pressure and the role of nitric oxide, an important physiological signaling molecule that plays a key role in IOP regulation in healthy eyes

  • Utilize results from peer-reviewed studies, including comparative studies of agents, in choosing therapies

  • Choose appropriate therapies based on understanding of mechanism(s) of action, safety, efficacy, compliance, and duration of effect

  • Among agents with maximum efficacy and safety, select those that minimize patient burden and maximize compliance

  • Implement evidence-based strategies for determining/achieving target IOP

  • Make evidence-based decisions about when to treat ocular hypertension

  • Explain the mechanism of action, benefits, and risks of established and new therapies, from medications that suppress aqueous humor production, such as beta blockers; to medications that increase aqueous outflow, such as prostaglandin analogs; to newer agents such as nitric oxide donating prostaglandin receptor agonists